ASH 2018 | Sorafenib for FLT3-ITD-positive AML

Andreas Burchert

Most patients with FLT3-ITD-positive acute myeloid leukemia (AML), who relapse after allogenic stem cell transplantation (ASCT) succumb to their disease. Here, Andreas Burchert, MD, of the University of Marburg, Marburg, Germany, discusses the SORMAIN trial (EUDRACT 2010-018539-16) assessing whether FLT3-ITD inhibition with sorafenib can prevent AML relapse, thus improving the outlook for patients in remission following ASCT. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Prof. Burchert reveals the practice-changing results showing sorafenib maintenance therapy after ASCT is feasible and significantly enhances OS in patients with FLT3-ITD-positive AML.

Share this video